Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 15, 2024

Treatment-Free Remission After a Second TKI Discontinuation Attempt in Patients With CML Retreated With Dasatinib



Additional Info

Disclosure statements are available on the authors' profiles:

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial
Leukemia 2024 Jan 26;[EPub Ahead of Print], H Flygt, S Söderlund, J Richter, S Saussele, P Koskenvesa, L Stenke, S Mustjoki, A Dimitrijevic, J Stentoft, W Majeed, L Roy, D Wolf, A Dreimane, BT Gjertsen, T Gedde-Dahl, E Ahlstrand, B Markevärn, H Hjorth-Hansen, J Janssen, U Olsson-Strömberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading